However, both companies will continue to collaborate in the field of prostate cancer.
Loic Maurel, president of management board at ExonHit, said: “ExonHit’s technology was able to produce a robust and reproducible test however, the final results from the colon cancer program did not reach the level of performance we were aiming to achieve. Therefore, we have decided together with bioMerieux to focus our efforts on the prostate cancer program.”
Stephane Bancel, CEO of bioMerieux, said: “Biomarker discovery is a strategic focus of innovation research for bioMerieux, but is a challenging scientific, medical and business endeavor. We made the decision to stop this Colon cancer screening Research program with ExonHit after reviewing the results of the clinical data. Our teams have learned a lot about this important disease. We look forward to continuing our collaboration together in the area of prostate cancer.”
ExonHit and bioMerieux collaboration is dedicated to the discovery of biomarkers for the detection of certain cancers.